Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 238, Issue -, Pages 114524
Publisher
Elsevier BV
Online
2022-06-08
DOI
10.1016/j.ejmech.2022.114524
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy
- (2022) Jifa Zhang et al. JOURNAL OF MEDICINAL CHEMISTRY
- AncPhore: A versatile tool for anchor pharmacophore steered drug discovery with applications in discovery of new inhibitors targeting metallo-β-lactamases and indoleamine/tryptophan 2,3-dioxygenases
- (2021) Qingqing Dai et al. Acta Pharmaceutica Sinica B
- The Ups, Downs and New Trends of IDO1 Inhibitors
- (2021) Shulun Chen et al. BIOORGANIC CHEMISTRY
- The emerging roles of IDO2 in cancer and its potential as a therapeutic target
- (2021) Pengcheng Li et al. BIOMEDICINE & PHARMACOTHERAPY
- Parallel discovery of selective and dual inhibitors of tryptophan dioxygenases IDO1 and TDO2 with a newly-modified enzymatic assay
- (2021) Rossella Capochiani de Iudicibus et al. BIOORGANIC & MEDICINAL CHEMISTRY
- X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson’s Disease
- (2021) Xiang-Li Ning et al. JOURNAL OF MEDICINAL CHEMISTRY
- Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma
- (2021) Yousef Zakharia et al. Journal for ImmunoTherapy of Cancer
- IDO1/TDO dual inhibitor RY103 targets Kyn-AhR pathway and exhibits preclinical efficacy on pancreatic cancer
- (2021) Heng Liang et al. CANCER LETTERS
- DYRK1A inhibitors for disease therapy: Current status and perspectives
- (2021) Tong Liu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor T cell immunity
- (2021) Madhav D. Sharma et al. IMMUNITY
- Discovery of the First Potent IDO1/IDO2 Dual Inhibitors: A Promising Strategy for Cancer Immunotherapy
- (2021) Xin He et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Novel Dual-Target Inhibitor of Bromodomain-Containing Protein 4/Casein Kinase 2 Inducing Apoptosis and Autophagy-Associated Cell Death for Triple-Negative Breast Cancer Therapy
- (2021) Jifa Zhang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure and Plasticity of Indoleamine 2,3-Dioxygenase 1 (IDO1)
- (2021) Ute F. Röhrig et al. JOURNAL OF MEDICINAL CHEMISTRY
- Implementation of the CYP Index for the Design of Selective Tryptophan-2,3-dioxygenase Inhibitors
- (2020) Brendan T. Parr et al. ACS Medicinal Chemistry Letters
- Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool
- (2020) Martina Mandarano et al. Frontiers in Immunology
- Synthesis of novel tryptanthrin derivatives as dual inhibitors of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase
- (2020) Yuanyuan Li et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Discovery and structure-activity relationship studies of 1-aryl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (Ido1) and trytophan 2,3-dioxygenase (TDO)
- (2020) Shulei Pan et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Tryptophan Metabolites Are Associated With Symptoms and Nigral Pathology in Parkinson's Disease
- (2020) Patrick L. Heilman et al. MOVEMENT DISORDERS
- Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase 1 (HDAC1) Dual Inhibitors Derived from the Natural Product Saprorthoquinone
- (2020) Yang Lin et al. MOLECULES
- Design, synthesis, and biological evaluation of a novel indoleamine 2,3-dioxigenase 1 (IDO1) and thioredoxin reductase (TrxR) dual inhibitor
- (2020) Qing-Zhu Fan et al. BIOORGANIC CHEMISTRY
- Novel BuChE-IDO1 inhibitors from sertaconazole: Virtual screening, chemical optimization and molecular modeling studies
- (2020) You Zhou et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Indoleamine and tryptophan 2,3-dioxygenases as important future therapeutic targets
- (2020) Ana Dolšak et al. PHARMACOLOGY & THERAPEUTICS
- Alantolactone promotes ER stress-mediated apoptosis by inhibition of TrxR1 in triple-negative breast cancer cell lines and in a mouse model
- (2019) Changtian Yin et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
- (2019) Michael Platten et al. NATURE REVIEWS DRUG DISCOVERY
- Investigation of indolamine 2, 3 dioxygenase (IDO-1 ) gene expression by real-time PCR among patients with lung cancer
- (2019) Mojtaba Haji Mazdarani et al. JOURNAL OF CELLULAR PHYSIOLOGY
- 4,6-Substituted-1H-Indazoles as potent IDO1/TDO dual inhibitors
- (2019) Lingling Yang et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Discovery of Clinical Candidate (1R,4r)-4-((R)-2-((S)-6-Fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl)cyclohexan-1-ol (Navoximod), a Potent and Selective Inhibitor of Indoleamine 2,3-Dioxygenase 1
- (2019) Sanjeev Kumar et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Imidazoisoindole Derivatives as Highly Potent and Orally Active Indoleamine-2,3-dioxygenase Inhibitors
- (2019) Wangyang Tu et al. ACS Medicinal Chemistry Letters
- Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
- (2019) Georgina V Long et al. LANCET ONCOLOGY
- Synthesis and in vivo antitumor evaluation of an orally active potent phosphonamidate derivative targeting IDO1/IDO2/TDO
- (2019) Xi Feng et al. BIOCHEMICAL PHARMACOLOGY
- N-Benzyl/Aryl Substituted Tryptanthrin as Dual Inhibitors of Indoleamine 2,3-Dioxygenase and Tryptophan 2,3-Dioxygenase
- (2019) Dan Yang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting the Kynurenine Pathway for the Treatment of Cisplatin-Resistant Lung Cancer
- (2019) Dan J. M. Nguyen et al. MOLECULAR CANCER RESEARCH
- Discovery and Characterisation of Dual Inhibitors of Tryptophan 2,3-Dioxygenase (TDO2) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Using Virtual Screening
- (2019) Suat Sari et al. MOLECULES
- Inhibition of the Nrf2-TrxR Axis Sensitizes the Drug-Resistant Chronic Myelogenous Leukemia Cell Line K562/G01 to Imatinib Treatments
- (2019) Lianrong Xu et al. Biomed Research International
- Olean-28,13b-olide 2 plays a role in cisplatin-mediated apoptosis and reverses cisplatin resistance in human lung cancer through multiple signaling pathways
- (2019) Bin Zhu et al. BIOCHEMICAL PHARMACOLOGY
- Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as IDO1/TDO dual inhibitors
- (2019) Guonan Cui et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Plasma activity of Thioredoxin Reductase as a Novel Biomarker in Gastric Cancer
- (2019) Wei Peng et al. Scientific Reports
- Investigation of multi-target-directed ligands (MTDLs) with butyrylcholinesterase (BuChE) and indoleamine 2,3-dioxygenase 1 (IDO1) inhibition: The design, synthesis of miconazole analogues targeting Alzheimer’s disease
- (2018) Xin Lu et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Recent discovery of indoleamine-2,3-dioxygenase 1 inhibitors targeting cancer immunotherapy
- (2018) Tianwei Weng et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Small molecule inhibitors of mammalian thioredoxin reductase as potential anticancer agents: An update
- (2018) Junmin Zhang et al. MEDICINAL RESEARCH REVIEWS
- Targeting the IDO1/TDO2–KYN–AhR Pathway for Cancer Immunotherapy – Challenges and Opportunities
- (2018) Jae Eun Cheong et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors
- (2018) Kun Fang et al. ACS Medicinal Chemistry Letters
- Antigen-Specific Antitumor Responses Induced by OX40 Agonist Are Enhanced by the IDO Inhibitor Indoximod
- (2018) Zuzana Berrong et al. Cancer Immunology Research
- HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response
- (2018) Xinfeng Liu et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
- (2018) Bruno Gomes et al. MOLECULAR CANCER THERAPEUTICS
- Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond
- (2018) Alexander J. Muller et al. Seminars in Immunopathology
- Induction of Oxidative Stress via Inhibition of Thioredoxin Reductase 1 is an Effective Therapeutic Approach for Hepatocellular Carcinoma
- (2018) Derek Lee et al. HEPATOLOGY
- High-resolution structures of inhibitor complexes of human indoleamine 2,3-dioxygenase 1 in a new crystal form
- (2018) Shukun Luo et al. Acta Crystallographica Section F-Structural Biology Communications
- IDO1: An important immunotherapy target in cancer treatment
- (2017) Fangxuan Li et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Discovery of a Small-Molecule Bromodomain-Containing Protein 4 (BRD4) Inhibitor That Induces AMP-Activated Protein Kinase-Modulated Autophagy-Associated Cell Death in Breast Cancer
- (2017) Liang Ouyang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia
- (2017) Jesper F. Havelund et al. JOURNAL OF NEUROCHEMISTRY
- Targeting TDO in cancer immunotherapy
- (2017) Cheng-Peng Yu et al. MEDICAL ONCOLOGY
- Discovery of IDO1 and DNA dual targeting antitumor agents
- (2017) Kun Fang et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- Targeting the Thioredoxin System for Cancer Therapy
- (2017) Junmin Zhang et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology
- (2017) Eddy W. Yue et al. ACS Medicinal Chemistry Letters
- Structural insights into substrate and inhibitor binding sites in human indoleamine 2,3-dioxygenase 1
- (2017) Ariel Lewis-Ballester et al. Nature Communications
- HDAC inhibitors enhance the immunotherapy response of melanoma cells
- (2017) Laurence Booth et al. Oncotarget
- ERK5 signalling rescues intestinal epithelial turnover and tumour cell proliferation upon ERK1/2 abrogation
- (2016) Petrus R. de Jong et al. Nature Communications
- The thioredoxin system in breast cancer cell invasion and migration
- (2016) Maneet Bhatia et al. Redox Biology
- Synthesis and Intracellular Redox Cycling of Natural Quinones and Their Analogues and Identification of Indoleamine-2,3-dioxygenase (IDO) as Potential Target for Anticancer Activity
- (2015) Christopher E. Blunt et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- A TDO2-AhR Signaling Axis Facilitates Anoikis Resistance and Metastasis in Triple-Negative Breast Cancer
- (2015) Nicholas C. D'Amato et al. CANCER RESEARCH
- Tryptophan-Degrading Enzymes in Tumoral Immune Resistance
- (2015) Nicolas van Baren et al. Frontiers in Immunology
- Expression of Class I Histone Deacetylases Indicates Poor Prognosis in Endometrioid Subtypes of Ovarian and Endometrial Carcinomas
- (2015) Wilko Weichert et al. NEOPLASIA
- Structural and functional analyses of human tryptophan 2,3-dioxygenase
- (2014) Bing Meng et al. PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS
- Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
- (2014) Stefani Spranger et al. Journal for ImmunoTherapy of Cancer
- The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma
- (2014) Minghui Li et al. Journal for ImmunoTherapy of Cancer
- Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry
- (2013) Hatem Soliman et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- IDO1 Metabolites Activate β-catenin Signaling to Promote Cancer Cell Proliferation and Colon Tumorigenesis in Mice
- (2013) Ameet I. Thaker et al. GASTROENTEROLOGY
- Metabolites of tryptophan catabolism are elevated in sera of patients with myelodysplastic syndromes and inhibit hematopoietic progenitor amplification
- (2013) Céline Berthon et al. LEUKEMIA RESEARCH
- Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion
- (2012) M. Platten et al. CANCER RESEARCH
- IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts Survival
- (2012) D. A. Wainwright et al. CLINICAL CANCER RESEARCH
- Studies on Tissue and Cellular Distribution of Indoleamine 2,3-Dioxygenase 2
- (2012) Masakazu Fukunaga et al. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
- Marine Natural Products and Other Derivatives as Potent Indoleamine 2,3-Dioxygenase Inhibitors
- (2012) Evelyne Delfourne MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Kynurenines in the mammalian brain: when physiology meets pathology
- (2012) Robert Schwarcz et al. NATURE REVIEWS NEUROSCIENCE
- Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
- (2012) L. Pilotte et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
- (2011) Christiane A. Opitz et al. NATURE
- Cancer immunotherapy – revisited
- (2011) W. Joost Lesterhuis et al. NATURE REVIEWS DRUG DISCOVERY
- Kynurenine and its metabolites in Alzheimer's disease patients
- (2010) E Gulaj et al. Advances in Medical Sciences
- Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
- (2010) X. Liu et al. BLOOD
- Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy
- (2010) Tomoko Inaba et al. GYNECOLOGIC ONCOLOGY
- An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
- (2010) J. D. Mezrich et al. JOURNAL OF IMMUNOLOGY
- IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism
- (2008) Stefan Löb et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men
- (2008) Xiang-Jiao Yang et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality
- (2007) L. K. Jasperson et al. BLOOD
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started